Mingrong Cheng

798 total citations · 1 hit paper
22 papers, 572 citations indexed

About

Mingrong Cheng is a scholar working on Molecular Biology, Epidemiology and Biomaterials. According to data from OpenAlex, Mingrong Cheng has authored 22 papers receiving a total of 572 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Epidemiology and 7 papers in Biomaterials. Recurrent topics in Mingrong Cheng's work include Nanoparticle-Based Drug Delivery (7 papers), Liver Disease Diagnosis and Treatment (4 papers) and Liver Disease and Transplantation (4 papers). Mingrong Cheng is often cited by papers focused on Nanoparticle-Based Drug Delivery (7 papers), Liver Disease Diagnosis and Treatment (4 papers) and Liver Disease and Transplantation (4 papers). Mingrong Cheng collaborates with scholars based in China, United Kingdom and United Arab Emirates. Mingrong Cheng's co-authors include Bing He, Kangkang Zhi, Hongzhi Xu, Han Jiang, Junqi Wu, Weiping Zhu, Wanqing Liao, Weihua Pan, Xinlin Zhu and Mingwei Du and has published in prestigious journals such as PLoS ONE, Molecular Cancer and European Journal of Pharmacology.

In The Last Decade

Mingrong Cheng

20 papers receiving 561 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnosis of invasive fungal infections: challenges and recent developments

2023 153 citations Wenjie Fang, Junqi Wu et al. Journal of Biomedical Science profile →

Peers

Countries citing papers authored by Mingrong Cheng

Since Specialization

Citations

This map shows the geographic impact of Mingrong Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingrong Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingrong Cheng more than expected).

Fields of papers citing papers by Mingrong Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mingrong Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingrong Cheng. The network helps show where Mingrong Cheng may publish in the future.

Co-authorship network of co-authors of Mingrong Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Mingrong Cheng. A scholar is included among the top collaborators of Mingrong Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mingrong Cheng. Mingrong Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Integrative transcriptome-proteome approach reveals key hypoxia-related features involved in the neuroprotective effects of Yang Xue oral liquid on Alzheimer’s and Parkinson’s disease 2024 ·Frontiers in Pharmacology ·Xiangyang Chen, Mingrong Cheng, Chenchen Tang, (unknown), (unknown), Yuan Gao, (unknown), Jian Chen	3
2	Diagnosis of invasive fungal infections: challenges and recent developments breakdown → 2023 ·Journal of Biomedical Science ·Wenjie Fang, Junqi Wu, Mingrong Cheng, Xinlin Zhu, Mingwei Du, (unknown), Wanqing Liao, Kangkang Zhi, Weihua Pan	153
3	Autologous bone marrow infusion via portal vein combined with splenectomy for decompensated liver cirrhosis: A retrospective study 2023 ·World Journal of Gastrointestinal Surgery ·Baochi Liu, Mingrong Cheng, (unknown), Lei Li, (unknown), Aijun Li, (unknown), Hui Zhang	0
4	Inhibitory of active dual cancer targeting 5-Fluorouracil nanoparticles on liver cancer in vitro and in vivo 2022 ·Frontiers in Oncology ·Mingrong Cheng, Dejian Dai	7
5	Autologous Bone Marrow Cell Infusion for the Treatment of Decompensated Liver Cirrhosis Patients With Type 2 Diabetes Mellitus 2021 ·Frontiers in Physiology ·Baochi Liu, Mingrong Cheng, (unknown), Lei Li, (unknown), (unknown)	0
6	Preoperative antiviral therapy and microvascular invasion in hepatitis B virus-related hepatocellular carcinoma: A meta-analysis 2020 ·European Journal of Pharmacology ·Zhenchang Wang, (unknown), Jinmei Zhang, (unknown), Shanshan Wu, Mingrong Cheng, Akshaya Srikanth Bhagavathula, Wafa Ali Aldhaleei, Cain C. T. Clark, (unknown)	8
7	Autologous bone marrow cell transplantation in the treatment of HIV patients with compensated cirrhosis 2020 ·Bioscience Reports ·Baochi Liu, Mingrong Cheng, Xiaohong Chen, Lei Li, (unknown), Shijia Wang, Ying Wang, Yufang Shi	3
8	Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo 2018 ·Cellular Physiology and Biochemistry ·Mingrong Cheng, (unknown), Kangkang Zhi, Baochi Liu, Weiping Zhu	18
9	Transition-metal-free, visible-light-mediated cyclization of o-azidoarylalkynes with aryl diazonium salts 2017 ·New Journal of Chemistry ·Cheng Jin, (unknown), (unknown), Mingrong Cheng	18
10	Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway 2016 ·Oncology Reports ·Weiping Zhu, (unknown), (unknown), De-Ning Ma, Mingrong Cheng, Huipeng Wang, Jiaying Zhao, (unknown), Zhijian Cheng	15
11	Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics 2014 ·International Journal of Nanomedicine ·Bing He, Mingrong Cheng, (unknown), Yong Wang, Hongzhi Xu, Han Jiang, Zhiping Zhang	27
12	Activation of cellular immunity and marked inhibition of liver cancer in a mouse model following gene therapy and tumor expression of GM-SCF, IL-21, and Rae-1 2013 ·Molecular Cancer ·Mingrong Cheng, Kangkang Zhi, Xiaoyan Gao, Bing He, Ying-Chun Li, Han Jiang, Zhiping Zhang, Yan Wu	8
13	Synthesis of liver-targeting dual-ligand modified GCGA/5-FU nanoparticles and their characteristics in vitro and in vivo 2013 ·International Journal of Nanomedicine ·Bing He, Mingrong Cheng, Xiaoyan Gao, Yong Wang, (unknown), Yingchun Li, Han Jiang, Zhiping Zhang	16
14	Synthesis of Glycyrrhetinic Acid-Modified Chitosan 5-Fluorouracil Nanoparticles and Its Inhibition of Liver Cancer Characteristics in Vitro and in Vivo 2013 ·Marine Drugs ·Mingrong Cheng, Xiaoyan Gao, Yong Wang, (unknown), Bing He, Hongzhi Xu, Yingchun Li, Han Jiang, (unknown)	61
15	5-Fluorouracil Nanoparticles Inhibit Hepatocellular Carcinoma via Activation of the p53 Pathway in the Orthotopic Transplant Mouse Model 2012 ·PLoS ONE ·Mingrong Cheng, Bing He, Tao Wan, Weiping Zhu, Han Jiang, Bingbing Zha, (unknown), (unknown), Qing Li, Wei Wang, Hongzhi Xu, (unknown)	59
16	Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects 2012 ·World Journal of Gastroenterology ·Mingrong Cheng	58
17	Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice 2012 ·Cancer Biology & Therapy ·Mingrong Cheng, Zheng Liu, Tao Wan, Bing He, Bingbing Zha, (unknown), (unknown), (unknown), Qing Li, Wei Wang, Hongzhi Xu, (unknown)	14
18	Synthesis of galactosylated chitosan/5‐fluorouracil nanoparticles and its characteristics,in vitroandin vivorelease studies 2012 ·Journal of Biomedical Materials Research Part B Applied Biomaterials ·Mingrong Cheng, Han Jiang, Qing Li, Bing He, Bingbing Zha, (unknown), (unknown), (unknown), Wei Wang, Hongzhi Xu, (unknown)	13
19	Design and synthesis of dual-ligand modified chitosan as a liver targeting vector 2011 ·Journal of Materials Science Materials in Medicine ·(unknown), Min Li, Tao Wan, Qichang Zheng, Mingrong Cheng, Shiqi Huang, Yong Wang	26
20	Synthesis and efficient hepatocyte targeting of galactosylated chitosan as a gene carrier in vitro and in vivo 2011 ·Journal of Biomedical Materials Research Part B Applied Biomaterials ·Mingrong Cheng, Qing Li, Tao Wan, (unknown), (unknown), Bing He, (unknown), Hongzhi Xu, Ye Tao, Bingbing Zha, (unknown), (unknown)	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact